Company profile for Corvus Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers, including refractory renal cell carcinoma and non-small cell lung cancer. Our seasoned team of biopharma industry leaders are dedicated to developing new oncology medicines for patie...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers, including refractory renal cell carcinoma and non-small cell lung cancer. Our seasoned team of biopharma industry leaders are dedicated to developing new oncology medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
863 Mitten Road, Suite 102 Burlingame, CA
Telephone
Telephone
650-900-4520
Client Website
Website
--
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/04/3180825/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179394/0/en/Corvus-Pharmaceuticals-to-Present-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-Exposition.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/31/3178244/0/en/Corvus-Pharmaceuticals-to-Present-at-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html

GLOBENEWSWIRE
31 Oct 2025

https://www.globenewswire.com/news-release/2025/10/28/3175918/0/en/Corvus-Pharmaceuticals-to-Provide-Business-Update-and-Third-Quarter-2025-Financial-Results-on-November-4-2025.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/10/17/3168712/0/en/Corvus-Pharmaceuticals-Announces-Presentation-of-Interim-Data-from-the-Phase-1b-2-Clinical-Trial-of-Ciforadenant-for-Patients-with-Metastatic-Renal-Cell-Cancer-at-the-European-Soci.html

GLOBENEWSWIRE
17 Oct 2025

https://www.globenewswire.com/news-release/2025/10/02/3160685/0/en/Corvus-Pharmaceuticals-Appoints-David-Moore-to-Board-of-Directors.html

GLOBENEWSWIRE
02 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty